Glycoconjugate ExPEC vaccine: Interim Phase I data

Interim data from a placebo-controlled, Swiss Phase I trial in 194 women affected by recurrent urinary tract infection (UTI) showed that the Glycoconjugate ExPEC vaccine produced a “robust” immune res...